Background and objectives Patients with the hereditary disease Alport syndrome commonly require renal replacement therapy (RRT) in the second or third decade of life. This study compared age at onset of RRT, renal allograft, and patient survival in men with Alport syndrome receiving various forms of RRT (peritoneal dialysis, hemodialysis, or transplantation) with those of men with other renal diseases.
Introduction
Alport syndrome is a hereditary nephropathy characterized by progressive renal failure, sensorineural deafness, and typical ocular abnormalities. It almost inevitably leads to ESRD during adolescence or early adulthood (1) (2) (3) . The disease is caused by mutations in type IV collagen genes (1, (4) (5) (6) . Eighty-five percent of Alport families have an X-linked (COL4A5 gene) and 15% an autosomal-recessive (COL4A3 or COL4A4 genes) pattern of inheritance (1, (7) (8) (9) (10) . Female heterozygous X-linked Alport carriers show a large interand intrafamilial variability of the clinical course and a more favorable prognosis (11, 12) . Heterozygous COL4A3/COL4A4 carriers develop thin basement membrane nephropathy (10, 12, 13) , which may lead to an increased risk for developing progressive CKD (12) . Thin basement membrane nephropathy is very common, with a prevalence ranging from 1% in the general population (13) to 5.2% in a series of transplant biopsies (14) . This high prevalence of heterozygous carriers among family members might affect the rate of living kidney donation in Alport families.
Patients with Alport syndrome who undergo kidney transplantation typically have a good outcome (15) . However, 2%-5% of males develop anti-glomerular basement (GBM) membrane disease early in the post-transplant period, resulting in rapid loss of the allograft (16) (17) (18) . Anti-GBM disease can recur earlier and behave more aggressively in subsequent transplants. Until the late 1990s, no therapy could be offered to patients with Alport syndrome to delay onset of kidney failure. Angiotensin-converting enzyme inhibitor therapy may delay disease progression, according to studies in both animal models (19) and humans (20) .
Data on patients with Alport syndrome undergoing renal replacement therapy (RRT) are scarce. Therefore, this study was launched to evaluate outcome of male patients with Alport syndrome receiving RRT using data collected by the European Renal AssociationEuropean Dialysis and Transplant Association (ERA-EDTA) Registry (21) . The study examines the time trends in age at onset of RRT of patients with Alport syndrome from 1990 to 2009 and compares the following outcomes among patients with Alport syndrome and matched controls with other renal diseases: overall patient survival during RRT, patient survival during dialysis, and patient and graft survival after renal transplantation.
Material and Methods

Data Collection
The ERA-EDTA Registry annually collects data on patients who start RRT and are listed in national and regional renal registries in Europe. Fourteen national or regional renal registries from 11 countries, which submitted individual patient data to the ERA-EDTA Registry from 1990 to 2009, participated in the study. These included the national registries of Austria, Denmark, Finland, Greece, Iceland, Norway, Sweden (from 1991), the Netherlands, and Scotland and the regional registries of Calabria in Italy (from 1997) and Andalusia (Basque country, from 1992), Catalonia, and Valencian Community (from 1992) in Spain. These registries report to cover almost 100% of the general population in their country. Moreover, after data are received, they are extensively checked within the ERA-EDTA registry (21) . Further details of the ERA-EDTA database and the methods used to collect and process data have been previously reported (22) .
Cases included only male patients with ESRD due to Alport syndrome (code 51, defined as Alport's syndrome/ hereditary nephritis with nerve deafness) who started RRT between January 1, 1990, and December 31, 2009, and were still alive at day 91 after start of RRT. Females with Alport syndrome (code 51) were excluded to avoid the inclusion of heterozygous female carriers of X-linked Alport syndrome, who have a different prognosis. As shown in Table  1 , controls included males undergoing RRT with ESRD due to causes other than Alport syndrome, who were still alive at day 91 after start of RRT. They were matched for age (per year), year at onset of RRT (within 2 years), and RRT modality at day 91 after onset of RRT (hemodialysis, peritoneal dialysis, and kidney transplantation). For each Alport case, five male controls were randomly selected from the same age, year, and modality categories. To compare survival after the first kidney transplant, a second cohort was composed of male patients with ESRD due to Alport syndrome who received a kidney transplant between January 1, 1990 , and December 31, 2009. For each of these Alport patients, five male controls with other causes of ESRD were randomly selected from the same age at transplantation (per year), year of transplantation (within 2 years), and donor kidney (living, deceased, and unknown) categories.
Statistical Analyses
Differences in patient characteristics between groups were examined using the chi-squared test. To detect points in time when the age at start of RRT increased more rapidly, a linear spline model was developed and fitted using the Transreg procedure in SAS software, version 9.2 (SAS Institute, Inc., Cary, NC). Here the dependent variable was the age at onset of RRT, and the spline transformation of the year of RRT initiation was the independent variable. The Kaplan-Meier method and Cox regression analyses were used to compare survival probabilities. Patients were followed until December 31, 2009. For the analysis of patient survival on RRT, the day at start of RRT was taken as the starting point, and the event studied was death. Reasons for censoring were recovery of renal function, loss to follow-up, and end of follow-up time. For the analysis of patient survival on dialysis, the first day on dialysis was the starting point, the event was death, and reasons for censoring were recovery of renal function, loss to followup, end of follow-up time, and renal transplantation. To account for renal transplantation as a competing risk for death while patients are undergoing dialysis, a competing risk analysis was also performed. For the analysis of patient and graft survival after transplantation, survival times were measured from the date of the first renal transplantation. The event of interest was death in patient survival analysis and graft failure or death in graft survival analysis. Reasons for censoring were loss to follow-up and end of follow-up time. For all models, interactions between Alport syndrome and the age at start of RRT, or the age at kidney transplantation, were examined to determine whether the association of Alport syndrome with outcome differed between younger and older patients.
Results
Between January 1, 1990, and December 31, 2009, 456 patients with ESRD due to Alport syndrome started RRT. A total of 2280 matched controls were included. Table 1 
Patient Survival on RRT
The total follow-up time of the 456 Alport patients was 3179 years; 38 patients died within the study period (1.20 deaths per 100 patient-years). The 2280 matched controls had a total follow-up time of 14,746 years, and 405 patients died (2.75 deaths per 100 patient-years). Only four (0.9%) of the Alport patients and 21 (1.1%) of the controls were censored because of loss to follow-up. Survival of patients with Alport syndrome was better than for the matched controls ( Figure 3A and Table 2 ; P,0.001). The distribution of causes of death did not differ significantly between the two groups (Table 3) , with cardiovascular disease and infections being the most common causes. Although we found a statistically significant interaction between Alport syndrome as primary renal disease and the age at start of RRT (P=0.026), the survival advantage of patients with Alport syndrome compared with matched controls was consistent in both younger and older patients starting RRT ( Figure 3B and Table 2 ). In addition, when stratified by period of RRT initiation, patients with Alport syndrome showed superior survival in both 1990-1999 and 2000-2009 ( Figure 3C and Table 2 
Patient Survival during Dialysis
At day 91 after the start of RRT, 395 of the 456 patients with Alport disease were receiving dialysis (hemodialysis, 264; peritoneal dialysis, 131) ( Table 1) . Survival of patients with Alport syndrome during dialysis was superior to that of matched controls, for both hemodialysis and peritoneal dialysis ( Figure 4 and Table 2 ). Of 131 Alport patients receiving peritoneal dialysis who were included in the analysis, only 2 died, compared with 91 of 655 matched controls; therefore, a reliable HR could not be calculated. Competing risk analysis with transplantation as the competing event confirmed these results (P,0.001). For patient survival with hemodialysis, we found a statistically significant interaction between Alport syndrome as primary renal disease and age at start RRT (P=0.020). However, we Table 2 demonstrate that patients with Alport syndrome had superior patient and graft survival. There was no statistically significant interaction between Alport syndrome as primary renal disease and age at kidney transplantation for graft and patient survival after transplantation. Patients with Alport syndrome received a kidney from a living donor less often than did matched controls (data not shown). Stratified analyses (Table 2) revealed no statistically significant difference in patient and graft survival between patients with Alport syndrome and matched controls after living-donor transplantation. In contrast, patient and graft survival were statistically significantly better in patients with Alport syndrome after deceased-donor transplantation (Table 2) .
Discussion
To our knowledge, this is the first study to investigate the epidemiology of ESRD due to Alport syndrome by using a large data set from the ERA-EDTA Registry, including individual data from European patients receiving RRT. Several outcome measures were evaluated, including patient survival on RRT and survival after kidney transplantation as the most relevant endpoints.
Patient survival on RRT (dialysis or kidney transplantation) was found to be superior for patients with Alport syndrome compared with matched controls with other diseases. One explanation for this superior outcome is the absence of other essential organ system involvement; this absence leads to less morbidity than do, for example, diabetes and systemic inflammatory diseases that cause kidney failure. Such inflammatory diseases, including lupus nephritis and vasculitis, are likely to be responsible for the inferior survival during dialysis and after kidney transplantation (23) . Further, these diseases require more aggressive pharmacologic therapy, potentially resulting in more severe adverse effects. In patients with congenital anomalies of the urinary tract and kidney, ESRD may also be associated with increased morbidity due to surgical procedures and infectious complications, which can be life-threatening. Patients with these and several other renal diseases have an increased risk for serious complications from the illness itself or adverse treatment effects, possibly with fatal consequences. Furthermore, patients with Alport syndrome are thought to benefit from the nonrecurrent character of their disease in their kidney allografts.
Of note, patients with Alport syndrome seem to do particularly well with peritoneal dialysis. Among these patients, the potentially better outcome associated with peritoneal dialysis compared with hemodialysis requires further study. The absolute risk for death in patients with Alport syndrome is lower than in matched controls. However, the relative distribution of causes of death from cardiovascular disease, infection, and suicide did not differ between patients with Alport syndrome and matched controls. The similar risk for death from cardiovascular disease is notable because previous unpublished work suggested that patients with Alport syndrome have an increased risk for vascular events; this elevated risk is presumably due to a less stable architecture of their vascular basement membranes, which lack the disulfidebonds of the a3/a4/a5 type IV collagen chains. This notion is supported by the observation of an increased risk for premature stroke in patients with mutations in the a1 chain type IV collagen (24) .
The relatively low rate of living-donor kidney transplants in patients with Alport syndrome is probably due to the genetic cause of disease, resulting in other affected family members and small family sizes. Nevertheless, overall kidney graft and patient survival after kidney transplantation were better in patients with Alport syndrome than in matched controls. However, patients with Alport syndrome who receive a transplant run the risk of developing post-transplant anti-GBM nephritis caused by circulating alloantibodies against the "normal" donorkidney GBM containing a3/a4/a5 type IV collagen chains. The immune system of patients with Alport syndrome recognizes these chains as foreign. Anti-GBM disease, which occurs in 2%-5% of patients with Alport syndrome who receive a transplant (15) (16) (17) (18) , might contribute to a possible lack of superior graft survival in patients with this syndrome compared with controls in the first 2 years after transplantation. In fact, the graft survival curve begins to diverge from that of controls approximately 3 years after transplantation ( Figure 5B ). An overall superior survival of patients with Alport syndrome after kidney transplantation in general is thought to be caused by a better preservation of general health (due to a lower burden of comorbid conditions and treatment complications) compared with patients with other underlying renal diseases, in addition to an enhanced graft survival. The median graft survival in 56 patients with Alport syndrome from the European Alport registry (20) was 19 years (unpublished data). Superior graft survival can be partly explained by the nonrecurrence of the genetic kidney disease in Alport syndrome.
It is encouraging that the age at which patients with Alport syndrome in Europe require RRT increased slightly starting in 2000 and has increased even more from 2005 onward (Figures 1 and 2) . It is conceivable that increasing use of renoprotective therapy with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers over the past two decades may have been beneficial in adolescents with Alport syndrome (12, 20) . In addition, earlier diagnosis and increased awareness of possible therapeutic options for Alport syndrome in recent years may have delayed the onset of RRT and improved outcome. Nevertheless, the data provide no evidence that the delay in onset of RRT is due to changes in clinical practice resulting in a later start of dialysis. Patient survival after initiation of RRT did not change over the two different periods (1990-1999 versus 2000-2009) in patients with Alport syndrome or in controls.
In this study, the controls were selected from the same age, year, and modality categories as patients with Alport syndrome. Although it would have been preferable to match with respect to comorbidity as well, these data were not available. Moreover, a previous study has shown that once age, sex, and primary renal disease are included in models for patient survival on RRT, comorbidity may add relatively little to the explanation of the variance in mortality (25) .
In conclusion, our data suggest that renal failure in patients with Alport syndrome may be delayed compared with previous decades. Patient survival with RRT did not improve over time, suggesting that patients with Alport syndrome may benefit most from pharmacologic treatments that contribute to the postponement of ESRD. However, the good prognosis of these patients on RRT found in our study should be balanced against the riskbenefit ratio of future therapies (26, 27) . Nevertheless, compared with patients who have other renal diseases, Parts of the registry data were made public in abstract form at the annual meetings of the German and American Societies of Nephrology, the German Association of Internal Medicine, the European Renal Association, the German Society of Pediatric Nephrology, and the International Pediatric Nephrology Association. 
